TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Immuron New U.S. Department of Defense Award & Clinical Trial Update

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Immuron Limited
Immuron New U.S. Department of Defense Award & Clinical Trial Update

Immuron Limited receives a U.S. Department of Defense subaward to develop oral therapeutics targeting Campylobacter and Shigella, with plans to produce hyper-immune bovine colostrum products for pre-clinical evaluation and potential military use.

Insights
IMRN   positive

Secured new research agreement with military research institutions, advancing therapeutic development and receiving funding for innovative infectious disease treatments